CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million

Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic...

Related Keywords

Rehovot ,Hamerkaz ,Israel ,Israeli ,John Mullaly ,Company Bioink ,Allergan ,Tel Aviv University ,John Mullaly At Lifesci Advisors ,Israeli Innovation Authority ,Exchange Commission ,Sheba Medical Center ,Plant Biotechnologies ,Chief Executive Officer ,Abbvie Agreement ,Lifesci Advisors ,Collplant Investor Relations ,Weizmann Science Park ,Markets ,